Month: September 2023

Allschwil, Switzerland, September 28, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine (NEJM), one of the world’s leading peer-reviewed medical journals.1 In the study, Basilea’s ceftobiprole, a beta-lactam antibiotic, was evaluated for the treatment of bacterial bloodstream infections caused by Staphylococcus aureus in adult patients, also known as Staphylococcus aureus bacteremia (SAB). ERADICATE is the largest registrational study for SAB conducted to date and ceftobiprole showed similar clinical benefit compared to daptomycin, which is a standard of care antibiotic in...

HONG KONG, Sept. 27, 2023 (GLOBE NEWSWIRE) — In a previous release issued under the same headline by VS Media Holdings Limited (NASDAQ: VSME) (“VS Media,” or the “Company”), there were inaccuracies regarding important dates. Please note that the Company’s shares are expected to begin trading on the Nasdaq Capital Market on September 28, 2023 not September 27, 2023. In addition, the Offering is expected to close on October 2, 2023 not September 29, 2023. The corrected release follows: VS Media Holdings Limited today announced the pricing of its initial public offering of 2,000,000 Class A ordinary shares at a price to the public of $5.00 per share for a total of $10,000,000 of gross proceeds to the Company (the “Offering”), before deducting underwriting discounts, commissions, and other Offering expenses. The shares...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. HAMILTON, Ontario, Sept. 27, 2023 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, is pleased to announce that it has entered into an engagement with PI Financial Corp. (“PI”) pursuant to which PI will act as agent for the Company on a “best efforts” agency basis in connection with a private placement of up to 10,000,000 units (the “Units”) of the Company at a price of $0.40 per Unit (the “Offering Price”) for gross proceeds...

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions. All of the shares are to be sold by Immunovant. Immunovant offered 7,370,000 shares of its common stock in the public offering, at an offering price of $38.00 per share. In addition, Immunovant has granted the underwriters for the public offering a 30-day option to purchase up to an additional 1,105,500 shares of its common stock at the public...

SYDNEY, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Lithium Power International Limited (ASX: LPI) (“Lithium Power” or “the Company”) refers to recent media speculation regarding discussions between Corporación Nacional del Cobre de Chile (“Codelco”) and Lithium Power about a potential transaction. Lithium Power confirms that it is in discussions with Codelco regarding a potential transaction. However, at this stage, discussions between Lithium Power and Codelco are incomplete and no agreement on terms has been reached. Codelco has been granted due diligence and is continuing to undertake its due diligence investigations. Lithium Power notes that there is no certainty that the discussions with Codelco will lead to consummation of a transaction. Lithium Power will continue to keep the market fully informed, in accordance with its...

BREXAFEMMECartonBREXAFEMMEBlister PackJERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tablets. During a review of manufacturing equipment and cleaning activities at a supplier, SCYNEXIS was made aware of potential cross-contamination risk with a non-antibacterial beta-lactam drug substance. This press release provides additional details on the voluntary product recall recently disclosed by SCYNEXIS. Risk Statement: The potential cross contamination with a non-antibacterial beta-lactam drug substance could lead to...

MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH, CMI, Head of Clinical Development and Medical Affairs will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst at the Chardan 7th Annual Genetic Medicines Conference being held October 2-3, 2023 in NYC. Details regarding the fireside chat are as follows: Date: October 2, 2023 Location: Westin Grand Central, New York, NY Time: 1:30 p.m. ET Webcast Link: https://ir.ocugen.com/events/event-details/chardans-7th-annual-genetic-medicines-conference In...

TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Celestica’s third quarter financial results and conference call will take place on Thursday, October 26. The conference call start time is 8:00am ET. Financial results will be released after market close on Wednesday, October 25. Participants are invited to join the live webcast at: https://viavid.webcasts.com/starthere.jsp?ei=1636786&tp_key=32afcf346f For those unable to participate, a recorded webcast will be available approximately two hours after completion of the call. To access the recorded webcast visit www.celestica.com. Contact Celestica Investor Relationsclsir@celestica.com